Drug Profile
Talampanel
Alternative Names: GYKI-53773; LY-300164Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator IVAX Drug Research Institute
- Developer Teva Pharmaceutical Industries
- Class Antiepileptic drugs; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Dyskinesias; Epilepsy; Glioblastoma; Multiple sclerosis
Most Recent Events
- 23 Jun 2010 Discontinued - Phase-II for Glioblastoma in USA (PO)
- 08 Jun 2010 Teva Pharmaceutical Industries terminates phase II trial [NCT00982150] in Amyotrophic Lateral Sclerosis in the USA, Canada, EU and Israel
- 18 May 2010 Interim efficacy and adverse event data from a phase II trial in Amyotrophic lateral sclerosis released by Teva